IGH/BCL2 PLUS Translocation

Hematoloji problari

IGH, 14q32.33, Green BCL2, 18q21.33, Red The IGH/BCL2 Plus product consists of probes, labelled in green, proximal to the Constant, and within the Variable segment of the IGH region and a 585kb probe, labelled in red, covering the BCL2 and KDSR genes. Probe information The t(14;18)(q32;q21) translocation involving the IGH (immunoglobulin heavy locus) gene at 14q32 and the BCL2 (BCL2 apoptosis regulator) gene at 18q21.33 is a recognised recurrent abnormality seen in B-cell malignancies. IGH-BCL2 rearrangements are observed in 70-95% of follicular lymphoma (FL) cases and 20-30% of diffuse large B-cell lymphoma (DLBCL)1. Presence of the t(14;18) translocation in DLBCL is a predictor of outcome and has a poor prognostic effect2. BCL2 translocations have also been implicated in chronic B-cell lymphoproliferative disease (CLPD) and also occur occasionally in chronic lymphocytic leukaemia (CLL)3.

Product code : LPH 071

Explanation
Downloadable Files
Order form

Probe specification

IGH, 14q32.33, Green
BCL2, 18q21.33, Red

The IGH/BCL2 Plus product consists of probes, labelled in green, proximal to the Constant, and within the Variable segment of the IGH region and a 585kb probe, labelled in red, covering the BCL2 and KDSR genes.

Probe information

The t(14;18)(q32;q21) translocation involving the IGH (immunoglobulin heavy locus) gene at 14q32 and the BCL2 (BCL2 apoptosis regulator) gene at 18q21.33 is a recognised recurrent abnormality seen in B-cell malignancies.

IGH-BCL2 rearrangements are observed in 70-95% of follicular lymphoma (FL) cases and 20-30% of diffuse large B-cell lymphoma (DLBCL)¹. Presence of the t(14;18) translocation in DLBCL is a predictor of outcome and has a poor prognostic effect². BCL2 translocations have also been implicated in chronic B-cell lymphoproliferative disease (CLPD) and also occur occasionally in chronic lymphocytic leukaemia (CLL)³.